Wednesday, September 24, 2008

Omeros Gets $20M In Debt

Seattle-based Omeros, which is developing biopharmaceuticals for treating inflammation and central nervous system disorders, said Wednesday that it has established a $20M, debt facility with BlueCrest Capital Finance. Omeros said that the debt includes a $5M term loan, plus the right to access up to another $15M. According to Omeros, it will use the debt to expand its clinical programs and advance its preclinical pipeline. Omeros is backed by Aravis Ventures, ARCH Venture Partners, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, Trevi Health Ventures, WRF Capital, and others.